Silexion Therapeutics Corp (SLXN) Stock Price, Quote & News

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 674 3430

Fax: 972 2 643 0982

Website: silexion.com

Address:

The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel

ZacksResearch Nov. 13 at 1:52 PM

$SLXN narrows its losses by 72% — is this the start of a turnaround? 🔄 The biotech posted a Q3 net loss of $3.3M vs. $11.9M a year ago, after completing a $9.5M public offering 💰. It’s also moving closer to Phase II/III trials for its siRNA cancer candidate SIL-204, with CRO support now locked in for 2026. See the upside Wall Street expects 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-20831&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_20831

0 · Reply

_ReddBullyz Nov. 12 at 4:27 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $FGI $BDRX $NAAS $SLXN Viewing>

0 · Reply

WallStWireAds Nov. 12 at 2:03 PM

$SLXN https://caplynx.io/DZpZHmO

0 · Reply

AStrokeOfLuck Oct. 31 at 9:43 PM

$SLXN https://www.sec.gov/Archives/edgar/data/2022416/000117891325003631/zk2533902.htm

1 · Reply

EZ_Money11 Oct. 14 at 11:18 AM

$SLXN Slap the ask get it moving! Over 5k shares I’m waiting for $5+

0 · Reply

ZacksResearch Oct. 10 at 2:00 PM

$SLXN down 87% YTD — can the biotech bounce back? ⛹️‍♂️ Earlier this year, the company executed a 1-for-15 reverse stock split to regain Nasdaq compliance ⚖️ — a key move to stay in the game. It also partnered with Catalent for formulation development and clinical manufacturing of its next-gen siRNA candidate 💊, SIL-204, which targets locally advanced pancreatic cancer and is on track to enter phase II/III studies by the first half of 2026. See the upside Wall Street expects 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-15483&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_15483

0 · Reply

Robotai Oct. 10 at 12:30 AM

$SLXN

0 · Reply

DreamCreator Oct. 9 at 8:44 PM

Keep a close watch on CMCT! $BDRX $NAAS $SLXN $AIHS !!

0 · Reply

Trader1141 Oct. 8 at 10:01 AM

$XBIO $SPRB $SLRX $SLXN Low float with recent news that never ran on is $SLXN … waiting ⏳

1 · Reply

SYC80 Oct. 7 at 8:33 AM

$SLXN waking up 😏

0 · Reply

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 30, 2025, 8:40 AM EDT - 6 weeks ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 25, 2025, 8:45 AM EDT - 7 weeks ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 11, 2025, 1:26 PM EDT - 2 months ago

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Sep 11, 2025, 9:17 AM EDT - 2 months ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 7:00 AM EDT - 2 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 4, 2025, 9:25 AM EDT - 2 months ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 2, 2025, 8:45 AM EDT - 2 months ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 3 months ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 PM EDT - 3 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 9:55 AM EDT - 3 months ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 16, 2025, 8:44 AM EDT - 4 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 9, 2025, 8:30 AM EDT - 4 months ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

May 22, 2025, 3:46 PM EDT - 6 months ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 21, 2025, 8:45 AM EDT - 6 months ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 13, 2025, 4:45 PM EDT - 6 months ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 23, 2025, 9:20 AM EDT - 7 months ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Mar 28, 2025, 8:30 AM EDT - 8 months ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 21, 2025, 8:30 AM EDT - 8 months ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 18, 2025, 4:29 PM EDT - 8 months ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 17, 2025, 8:15 AM EDT - 8 months ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 5, 2025, 12:05 PM EST - 9 months ago

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Mar 5, 2025, 8:30 AM EST - 9 months ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 3, 2025, 8:30 AM EST - 9 months ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Feb 25, 2025, 8:30 AM EST - 9 months ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Jan 29, 2025, 5:30 PM EST - 10 months ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 9:59 AM EST - 10 months ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 28, 2025, 8:29 AM EST - 10 months ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 16, 2025, 12:08 PM EST - 10 months ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 11:04 AM EST - 10 months ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 8:51 AM EST - 10 months ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Jan 15, 2025, 8:00 PM EST - 10 months ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 4:01 PM EST - 10 months ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 13, 2025, 7:50 AM EST - 10 months ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Dec 17, 2024, 9:36 AM EST - 11 months ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Sep 24, 2024, 9:25 AM EDT - 1 year ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

ZacksResearch Nov. 13 at 1:52 PM

0 · Reply

_ReddBullyz Nov. 12 at 4:27 PM

Gotta give it to @Invinc1ble dude’s been on a hot streak 🔥 Worth a follow! $FGI $BDRX $NAAS $SLXN Viewing>

0 · Reply

WallStWireAds Nov. 12 at 2:03 PM

$SLXN https://caplynx.io/DZpZHmO

0 · Reply

AStrokeOfLuck Oct. 31 at 9:43 PM

$SLXN https://www.sec.gov/Archives/edgar/data/2022416/000117891325003631/zk2533902.htm

1 · Reply

EZ_Money11 Oct. 14 at 11:18 AM

$SLXN Slap the ask get it moving! Over 5k shares I’m waiting for $5+

0 · Reply

ZacksResearch Oct. 10 at 2:00 PM

0 · Reply

Robotai Oct. 10 at 12:30 AM

$SLXN

0 · Reply

DreamCreator Oct. 9 at 8:44 PM

Keep a close watch on CMCT! $BDRX $NAAS $SLXN $AIHS !!

0 · Reply

Trader1141 Oct. 8 at 10:01 AM

$XBIO $SPRB $SLRX $SLXN Low float with recent news that never ran on is $SLXN … waiting ⏳

1 · Reply

SYC80 Oct. 7 at 8:33 AM

$SLXN waking up 😏

0 · Reply

athebeast Oct. 6 at 2:33 PM

$ADTX Same business with $SLXN that's why I just short them

0 · Reply

BullsGame Oct. 2 at 3:39 PM

$SLXN Slow but steady

2 · Reply

DiMaMar Oct. 1 at 5:15 PM

$SLXN https://finance.yahoo.com/news/silexion-therapeutics-announces-positive-human-124000744.html

0 · Reply

debbiekatz Oct. 1 at 5:07 PM

$SLXN at 3.72. keep swinging. posted here at 3.36

0 · Reply

zsc Oct. 1 at 4:13 PM

$SLXN - https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-silexion-therapeutics-promising-preclinical-data-and-strategic-trial-plans-boost-investment-appeal-ratings?mod=mw_quote_news

0 · Reply

StockRedBaron Oct. 1 at 11:49 AM

$SLXN Just emailed out by Parisi: Silexion Therapeutics Corp (SLXN - $3.40 - Buy - $24.00 PT): Additional Pre-Clinical Data for SIL-204 Finds Pan-KRAS Activity Across Multiple Cancer Types & KRAS Mutations (Analyst: Naz Rahman, CFA)

0 · Reply

EZ_Money11 Oct. 1 at 2:48 AM

$SLXN $6.70’s fill the gap! 🎯

0 · Reply

debbiekatz Sep. 30 at 9:13 PM

nice pop for $SLXN today hitting 5.2 earlier- last posted for team at 3.57 on 9/23 for 46% gain. it's at 3.36 now.

1 · Reply

DekmarTrades Sep. 30 at 8:13 PM

I LOVE THIS TIME OF THE YEAR! I trade multiple times throughout the day and now I am on a 7 day WINNING STREAK! Volume is high, news is hot, and there are so many trades early in the morning! $NUWE $SLXN $WOLF

0 · Reply

TheBigSmallBigShort Sep. 30 at 3:52 PM

$SLXN I'm out, fck this

0 · Reply

TheBigSmallBigShort Sep. 30 at 3:17 PM

$SLXN come on go up

0 · Reply

Unalloyed Sep. 30 at 2:54 PM

$SLXN

0 · Reply

Market Cap	8.97M
Revenue (ttm)	0.00
Net Income (ttm)	-16.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	26.58

Volume	65,100
Avg Vol	601,988
Day's Range	N/A - N/A
Shares Out	3.13M
Stochastic %K	38%
Beta	-0.07
Analysts	Strong Sell
Price Target	$24.00